The iCMLf is seeking collaborators to join the iCMLf Cure Consortium (iC3), a global, multidisciplinary initiative focused on achieving a cure for CML.

Background

Over the past two decades, tyrosine kinase inhibitors have transformed CML into a manageable disease. Yet for most patients, cure remains elusive. Nearly half of those who achieve deep molecular response relapse after stopping therapy, reflecting the persistence of leukemia stem cells and their supportive microenvironment. Lifelong treatment carries clinical, psychological, and economic burdens and remains inaccessible or unsustainable in many parts of the world. A cure, therefore, is not only a scientific goal, but a global equity imperative.

Read more